Institute for Neurodegenerative Disorders — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications2liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
[18F] MNI-558This research will look at how the brain may change in people with Alzheimer disease (AD). The purpose of this research is to find out whether changes in the brain in people with Alzheimer disease can be detected using a brain imaging test. Most people with Alzheimer disease have changes in the brain that result in deposits of a protein called beta-amyloid. In this study, the investigators will be using a radioactive drug, \[18F\]MNI-558 that binds to beta-amyloid. This drug is experimental and has not been approved by the FDA. Brain imaging using PET (positron emission tomography) will be done to see if the investigators can evaluate the areas of beta-amyloid in the subjects with Alzheimer disease. The investigators will compare these scans with those done in healthy normal volunteers. PET is a brain-scanning test used in medicine and scientific research to see how the brain is working. The PET imaging test used in this study is not being done for diagnostic purposes.	Alzheimer	Phase 1	À vérifier	United States	À vérifier
[18F] MNI-558This research will look at how the brain may change in people with Alzheimer disease (AD). The purpose of this research is to find out whether changes in the brain in people with Alzheimer disease can be detected using a brain imaging test. Most people with Alzheimer disease have changes in the brain that result in deposits of a protein called beta-amyloid. In this study, the investigators will be using a radioactive drug, \[18F\]MNI-558 that binds to beta-amyloid. This drug is experimental and has not been approved by the FDA. Brain imaging using PET (positron emission tomography) will be done to see if the investigators can evaluate the areas of beta-amyloid in the subjects with Alzheimer disease. The investigators will compare these scans with those done in healthy normal volunteers. PET is a brain-scanning test used in medicine and scientific research to see how the brain is working. The PET imaging test used in this study is not being done for diagnostic purposes.	Alzheimer	Phase 1	À vérifier	United States	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
[18F] MNI-558	Alzheimer	Phase 1	NCT01217021	Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558	COMPLETED

Publications

2

Molécule	Indication / population	Titre	Journal	Date
[18F] MNI-558		Effect of genetic factors on [F]FDG PET metabolic phenotypes in dementia with Lewy bodies.	European journal of nuclear medicine and molecular imaging
[18F] MNI-558		Cost-effectiveness of preoperative parathyroid imaging in primary hyperparathyroidism: A synthesis of eight health-economic analyses.	European journal of nuclear medicine and molecular imaging